Free tool
FAERS Monitor: Vasopressin In Sodium Chloride 0.9%
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217766 or its brand name (Vasopressin In Sodium Chloride 0.9%, Vasopressin). Reports on generic versions are filed under their own applications.
Reports
4,378
Serious
4,221
96% of reports
Hospitalization
2,552
Death reported
1,722
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,358
- off label use551
- hypotension509
- cardiogenic shock427
- multiple organ dysfunction syndrome423
- sepsis413
- condition aggravated401
- toxicity to various agents342
- acute kidney injury340
- stress319
- vomiting319
- abdominal pain301
- general physical health deterioration297
- ascites293
- hyponatraemia291
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 17 |
| 2006 | 28 |
| 2007 | 32 |
| 2008 | 26 |
| 2009 | 43 |
| 2010 | 42 |
| 2011 | 134 |
| 2012 | 71 |
| 2013 | 36 |
| 2014 | 88 |
| 2015 | 67 |
| 2016 | 93 |
| 2017 | 144 |
| 2018 | 164 |
| 2019 | 169 |
| 2020 | 387 |
| 2021 | 615 |
| 2022 | 415 |
| 2023 | 535 |
| 2024 | 449 |
| 2025 | 512 |
| 2026 | 297 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,781 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cardiogenic shockSignal | 427 | 147.3 | 134.4 | 60,100 |
| multiple organ dysfunction syndromeSignal | 423 | 72.8 | 66.5 | 29,482 |
| ascitesSignal | 293 | 48.4 | 43.3 | 13,424 |
| hyponatraemiaSignal | 291 | 24.9 | 22.3 | 6,649 |
| stressSignal | 319 | 21.3 | 19.2 | 6,160 |
| sepsisSignal | 413 | 17.9 | 16.3 | 6,563 |
| general physical health deteriorationSignal | 297 | 12.4 | 11.1 | 3,099 |
| hypotensionSignal | 509 | 12.2 | 11.3 | 5,269 |
| acute kidney injurySignal | 340 | 10.7 | 9.7 | 2,994 |
| toxicity to various agentsSignal | 342 | 9.8 | 8.8 | 2,697 |
| condition aggravatedSignal | 401 | 6.3 | 5.8 | 1,824 |
| abdominal painSignal | 301 | 6.2 | 5.6 | 1,327 |
| drug ineffectiveSignal | 1,358 | 5.0 | 4.7 | 4,564 |
| vomitingSignal | 319 | 3.3 | 2.9 | 509 |
| off label useSignal | 551 | 3.0 | 2.8 | 776 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.